Gary6474 Posted - 18 hours ago

$LFCR Anyone else riding this to $8 with me?

Gary6474 Posted - 1 day ago

$LFCR $10 coming soon on this

vu_jade Posted - 1 day ago

$LFCR hit the scans

VaingloryInvestor Posted - 5 days ago

$LFCR under 5.5

BioTuesdays Posted - 2 weeks ago

Lifecore Biomedical has announced the appointments of Thomas Guldager as vice president of operations and Jackie Klecker as executive vice president of quality development services $LFCR https://biotuesdays.com/2024/11/04/lifecore-appoints-thomas-guldager-as-vp-operations-names-jackie-klecker-as-evp-quality/

EarningsCentral Posted - 10/23/24

$LFCR Earnings Call Recap for Q1 2025 https://youtu.be/Jy8C1TpvQhU

11thestate Posted - 1 month ago

$LFCR stockholder filed a claim against Lifecore Biomedical for weak controls that led to inaccurate statements and overstated prospects. You can join this case to be notified about potential recovery: https://11thestate.com/cases/lifecore-investor-suit

SmartContent Posted - 1 month ago

INMB Strong upside as Alzheimer’s and cancer therapies show promise with buy ratings from analysts. UGRO Expanding into new sectors with major contracts, including P.F. Chang’s and municipal projects. LFMD Telehealth and weight management programs continue to drive growth with high demand for GLP-1 treatments. GNSS Securing critical emergency communication contracts, bolstering leadership in public safety technology. OSS Strengthening defense contracts with rugged AI computing solutions for military applications. $MODD FDA-approved insulin pump MODD1 is well-positioned to capture growing diabetes market share. $STTK Insider buying signals confidence as the company shifts focus to autoimmune therapies post-restructuring. $LFCR Scaling contract development with multimillion-dollar deals and expanded production capacity.

G101SPM Posted - 1 month ago

#INSIDERS $LFCR 10% owners -- Legion Partners and Wynnefield Partners affirmed the purchase of 1,756,097 shares combined worth approximately $7.2 mln. $DAKT VP of Manufacturing sold 15,400 shares at $13.2783 worth approximately $204K. $DFH 10% owner sold 25,829 shares of Class A common stock at $33.22 - $35.15 worth approximately $888K. MPWR EVP, WW Sales & Marketing sold 11,000 shares at $925.89 - $935.00 worth approximately $10.2 mln.

FilingFact Posted - 1 month ago

$LFCR According to https://www.filingfact.com these are some of the top facts from the last report: Positive - During the year ended May 28, 2023, the Company entered into agreements for the sale or disposition of all subsidiaries within the Curation Foods business, which was completed during the year ended May 26, 2024 - The improvement in gross profit percentage is attributed to increased CDMO revenue gross profit due to favorable sales mix and price increases [...]. Negative - The company's principal executive officer and principal financial officer have concluded that its disclosure controls and procedures were not effective due to material weaknesses in internal control over financial reporting. - The SEC issued a subpoena to the Company seeking documents and information concerning a financial statement restatement. This information is important for investors as it indicates that the company is under investigation by the SEC, which could lead to potential fines or other penalties.

DonCorleone77 Posted - 1 month ago

$LFCR Lifecore reiterates FY25 revenue view $126.5M - $130M, consensus $127.56M For the full fiscal year 2025, the company is reiterating is financial guidance and expects revenue to be approximately $126.5 to $130 million and Adjusted EBITDA to be in the range of $19 to $21 million. This guidance takes into consideration existing market forces, contracts, timing of customer orders, and the company's current beliefs and estimations with respect to success and timing related to growing and diversifying the company's new business development revenue. Experience shows that a new business development organization, as there is at Lifecore, usually takes multiple quarters to optimize performance. The company cautions against extrapolating quarterly results to estimate full year results.

DonCorleone77 Posted - 1 month ago

$LFCR Lifecore reports Q1 EPS (53c) vs. (35c) last year Reports Q1 revenue $24.7M, consensus $23.19M. "I joined Lifecore last spring with a commitment to position the company for long-term success. To that end, we implemented a growth strategy based on three primary efforts: maximizing our existing business and customer base; advancing our development pipeline toward commercialization; and aggressively pursuing new business. I am pleased to report that, during the first quarter, Lifecore's operational and business development achievements supported each of these priorities," stated Paul Josephs, CEO. "Regarding operations. the company recently completed the installation and qualification of its high-speed, multi-purpose 5-head isolator filler, which is now GMP-ready. This new system positions the company to offer existing and future customers the speed and aseptic isolation benefits associated with this state-of-the-art, closed-system platform. With the addition of the 5-head isolator filler, which is designed for fill/finish activities for vials, cartridges, and pre-filled syringes, the company has more than doubled its prior capacity, significantly increasing our maximum revenue generating potential to up to approximately $300 million annually. This new system not only expands Lifecore's leadership in the fill/finish of highly viscous, complex formulations, but we believe it will also create an opportunity to win new, previously unsupported business, including fulfilling the needs of customers with less viscous, less complex protein, peptide and antibody products. We have already received significant interest from existing as well as new customers who are interested in accessing our state-of-the-art isolator filling system. With respect to business development, our team had a very solid first quarter. During the period, the company signed four new customers, including an exciting new program with Lindy Biosciences that will be focused on streamlining the formulation process for Lindy's innovative microglassification technology and scaling it for commercial manufacturing. During the quarter, we also signed numerous expansion agreements for existing customer projects. Importantly, the company increased investment in both our business development infrastructure and outreach. During the first quarter, the company added two new sales representatives who are increasing our reach in key pharma and biotech hubs in the U.S., and we plan to add at least one industry veteran to this team to provide an additional resource to maximize the sizable opportunity in front of us. In addition, the company is elevating its participation in industry conferences and events in the U.S and abroad. Our team is aggressively working to fill the plant's capacity, and though it is early, we are pleased to see our business development pipeline improving in terms of the quantity of opportunities that we are reviewing. To support the ongoing execution of our growth strategy, Lifecore today announced the successful closing of a private placement of 5,928,775 shares of its common stock with new and existing investors raising approximately $24.3 million. We believe this reflects the support that our shareholders have for our new management, our plan for value creation, and the tremendous opportunity we have in this growing market. We are grateful for this show of confidence. Importantly, we believe these funds, along with other potential non-dilutive actions available to the Company, will provide the financial stability needed to allow management to focus on growing the business aggressively and without distraction. Today, I am pleased to report that in my first 100 days, Lifecore has streamlined its operations, added talented leaders to the organization, signed multiple new customers, regained compliance with Nasdaq's listing requirements, and successfully raised funds. We have great optimism regarding the opportunity ahead, with this backdrop, we are reaffirming guidance for fiscal year 2025 for both revenue and Adjusted EBITDA. Looking forward we have established medium term financial objectives targeting double digit revenue CAGR and Adjusted EBITDA margins in line with those of our peers, which we expect to discuss in further detail at our future Investors Day in November. We are very pleased with the achievements during the period, all of which, I believe, have strengthened our potential to achieving sustainable growth in the coming years."

newsfile_corp Posted - 09/27/24

https://nfne.ws/218440 $LFCR @BGandG_Law #Banking #FinancialServices #NASDAQ #Investing

newsfile_corp Posted - 09/26/24

https://nfne.ws/218438 $LFCR @BGandG_Law #Banking #FinancialServices #NASDAQ #Investing

11thestate Posted - 2 months ago

$LFCR stockholder filed a claim against Lifecore Biomedical for poor controls that resulted in inaccurate statements and inflated prospects You can join this case to be notified about potential recovery: https://11thestate.com/cases/lifecore-investor-suit

Stock_Titan Posted - 2 months ago

$LFCR Lifecore Biomedical Announces High-Speed, Multi-Purpose 5-Head Isolator Filler is GMP-Ready and Operational https://www.stocktitan.net/news/LFCR/lifecore-biomedical-announces-high-speed-multi-purpose-5-head-kkqwqac9c916.html

Winning_calls Posted - 2 months ago

$LFCR 😘😘😘

Winning_calls Posted - 2 months ago

$LFCR pick me up @ $4.85😘😘

parababolicprofittaker Posted - 2 months ago

$INBS I got in at 2.10 to last night 4.00 on Monday but I want 10.00 I know it can go up more $BURU 1.73+ Monday $TNXP 0.25+ Monday $ALBT 0.50+ $LFCR 10.00+ Good luck you all. On Monday see you than

11thestate Posted - 2 months ago

$LFCR stockholder filed a claim against Lifecore Biomedical for weak controls that led to inaccurate statements and overstated prospects. You can join this case to be notified about potential recovery: https://11thestate.com/cases/lifecore-investor-suit

DomeniaSalvia Posted - 2 months ago

$LFCR Focused on delivering advanced clinical research services, this stock is essential for biotech companies developing new therapies. A solid pick for those interested in healthcare services. Check out my website, link in bio.

geepeez Posted - 08/30/24

$LFCR this company is going to be growing revs really fast in next 2 years. Yes they have debt that's because they spent Capex on the new facility

Stock_Titan Posted - 08/29/24

$LFCR Lifecore Biomedical Announces Chief Financial Officer Transition https://www.stocktitan.net/news/LFCR/lifecore-biomedical-announces-chief-financial-officer-cekf0axjrtio.html

Fullratio Posted - 08/28/24

$LFCR price to sales (P/S) is 53% lower than its 5-year quarterly average of 2.4 and 44% lower than its last 4 quarters average of 2.0: https://fullratio.com/stocks/nasdaq-lfcr/lifecore-biomedical

_www_larval_com_ Posted - 08/27/24

$JZXN 4%[-29%] $FEBO 4%[16%] $LFCR -3%[-23%] most notable movement into the final minutes of trading.

Stocksrunner Posted - 08/27/24

Today, several stocks are showing large price swings between their intraday highs and lows, highlighting volatility and potential trading opportunities. Keep an eye on these symbols: $LFCR $VOXX $ENSC $JZXN $EAF

1UpOnWallStreet Posted - 08/27/24

$LFCR Recovery buy now.

_www_larval_com_ Posted - 08/27/24

$LFCR just stumbled -8% lower to -24% (~64Kv) a few minutes ago, 09/20 options, follow for more volatility.

Profitrip Posted - 08/27/24

$GOTU $LFCR $TCOM reported earnings on watch

DonCorleone77 Posted - 08/26/24

$LFCR Lifecore sees FY25 revenue $126.5M-$130M, one estimate $137.98M Sees FY25 adjusted EBITDA $19M-$21M.